Karuna Therapeutics KRTX

$ 329.83 0.0%

Annual report 2023
added 02-22-2024

Karuna Therapeutics Financial Statements 2011-2024 | KRTX

Annual Financial Statements Karuna Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	11.8 B	6.07 B	3.06 B	3.3 B	1.13 B	-	-	-	-	-	-	-	-
Shares	37 M	31.6 M	29.1 M	26.4 M	12 M	-	-	-	-	-	-	-	-
Historical Prices	319	192	105	125	87.3	-	-	-	-	-	-	-	-
Net Income	-434 M	-276 M	-144 M	-68.6 M	-44 M	-17.5 M	-6.03 M	-	-	-	-	-	-
Revenue	654 K	10.6 M	37 M	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-495 M	-290 M	-144 M	-71.8 M	-45.4 M	-14.5 M	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-493 M	-289 M	-143 M	-71.7 M	-45.3 M	-14.5 M	-4.8 M	-	-	-	-	-	-
Operating Expenses	495 M	300 M	181 M	71.8 M	45.4 M	-	-	-	-	-	-	-	-
General and Administrative Expenses	131 M	76.1 M	52.6 M	28.4 M	20.9 M	2.97 M	1.19 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Karuna Therapeutics

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	37.7 M	37.5 M	34.8 M	34.5 M	32.3 M	29.9 M	29.8 M	29.8 M	29.6 M	29.5 M	27.8 M	27 M	26.7 M	26.2 M	26 M	26 M	22.9 M	104 K	2.68 K	12	5	12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-119 M	-103 M	-97.6 M	-	-77 M	-64.9 M	-58.2 M	-	-50.9 M	-34.4 M	-30.5 M	-	-18.8 M	-17 M	-8.66 M	-	-9.04 M	-15.1 M	-12 M	-	-6.24 M	-539 K	-2.41 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	654 K	-	81 K	5.28 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-136 M	-120 M	-109 M	-	-81 M	-65.1 M	-58.6 M	-	-51.2 M	-34.5 M	-30 M	-	-19.5 M	-17.8 M	-10.1 M	-	-9.9 M	-15.1 M	-11.6 M	-	-2.47 M	-2.43 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-109 M	-	-80.2 M	-64.5 M	-58.3 M	-	-50.9 M	-34.4 M	-29.9 M	-	-19.4 M	-17.8 M	-10 M	-	-9.86 M	-15 M	-11.6 M	-	-2.47 M	-2.43 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	136 M	120 M	110 M	-	81.1 M	70.3 M	58.6 M	-	51.2 M	34.5 M	30 M	-	19.5 M	17.8 M	10.1 M	-	9.9 M	15.1 M	11.6 M	-	2.47 M	2.43 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	32.3 M	27.4 M	24.3 M	-	19.1 M	17.8 M	14.8 M	-	12.4 M	10.4 M	9.78 M	-	6.94 M	7.01 M	5.64 M	-	4.1 M	8.29 M	4.61 M	-	1.06 M	256 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency